Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as a percentage of revenue in the same period.
| Tick rows to compare them in a chart (up to 4) | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,020.3% | -441.9% | -225.9% | -27.6% | 20.5% | -29.3% | -45.1% | -77.4% | -240.8% | -240.8% | -390.9% | -241.7% | -1,075.2% | -1,736.9% | -907.0% | |
| 54.1% | 57.3% | 30.3% | 14.5% | 10.2% | 12.9% | 13.5% | 20.6% | 54.8% | 54.8% | 96.5% | 40.0% | 107.1% | 115.3% | 33.0% | |
| 12.4% | 11.1% | 12.8% | 31.1% | 57.8% | 27.7% | 22.8% | 29.3% | 57.4% | 57.4% | 97.5% | 37.9% | 158.8% | 241.3% | 112.2% | |
| – | – | – | 54.3% | 29.7% | 33.6% | 32.0% | 69.1% | 467.8% | 149.8% | 82.0% | 40.2% | – | – | – | |
| -58.6% | 44.4% | -35.0% | 17.3% | 33.9% | -9.3% | -32.3% | -12.4% | -64.6% | -64.6% | -5.6% | -132.7% | 274.2% | 115.2% | 68.4% | |
| 162.3% | 53.8% | 6.4% | 8.9% | 7.3% | 16.6% | 20.2% | 25.9% | 23.5% | 23.5% | 50.8% | 18.3% | 24.7% | 218.7% | 20.6% | |
| -799.9% | -169.7% | -941.3% | -36.2% | -150.2% | -14.9% | 45.2% | -94.2% | 86.8% | 86.8% | -522.5% | 841.4% | -49.6% | -527.7% | -15.9% | |
| – | – | 635.1% | 9.7% | – | 22.0% | 3.3% | – | – | – | – | – | – | – | – | |
| – | – | 0.0% | -0.8% | 197.4% | -0.3% | -0.2% | 1.5% | 1.0% | 109.8% | 4.3% | 0.0% | 0.0% | 0.0% | -22.7% | |
| – | – | – | -3.1% | -1.8% | -0.2% | -0.3% | 136.7% | 3.8% | -7.5% | -3.3% | -577.1% | -694.3% | 0.0% | 958.5% | |
| 1,848.4% | 545.4% | 1,331.9% | 33.4% | 192.0% | 6.3% | 1.9% | 192.9% | 102.2% | 102.2% | 849.4% | -577.1% | 475.3% | 2,817.4% | 929.9% | |
| 28.2% | -66.2% | 164.6% | -30.6% | 62.4% | -38.3% | 2.4% | 21.6% | -50.6% | -50.6% | -62.4% | 19.5% | -654.6% | 552.1% | 7.4% | |
| -1,182.6% | -495.7% | -232.4% | -36.5% | 13.2% | -45.9% | -65.3% | -103.3% | -264.3% | -264.3% | -441.7% | -260.0% | -1,099.9% | -1,955.6% | -927.6% |
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.